Mevidalen

Phase 2Small molecule

Eli Lilly

Mevidalen is one of 40 small molecule programs targeting Alzheimer's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer's DiseaseActive, not recruiting

Alzheimer's DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

59 competitors in Alzheimer's Disease

#DrugCompanyPhaseTrials

Aricept

Eisai

Approved

31 2

Leqembi

Eisai

Phase 3

7 3

Nuplazid

AACADIA Pharmaceuticals Inc.

Ozempic

3 5

Qalsody

Biogen

Phase 3

1 6

Namenda

AbbVie

Phase 2

2 7

Leukine

Sanofi

Phase 2

1 8

Briviact

UCB

Phase 2

1 9

Niacor

AbbVie

Phase 2

1 10

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alzheimer's Disease1 trial

A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT06538116·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mevidalen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mevidalen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mevidalen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

Mevidalen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News